Self-injectable epinephrine for first-aid management of anaphylaxis

Scott H. Sicherer, F. Estelle R. Simons, Paul V. Williams, Sami L. Bahna, Bradley E. Chipps, Mary Beth Fasano, Mitchell R. Lester, Frank S. Virant, Michael J. Welch, John M. Kelso, Todd A. Mahr, Dennis Randall Ownby, Gary S. Rachelefsky, Debra Burrowes

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Anaphylaxis is a severe, potentially fatal systemic allergic reaction that is rapid in onset and may cause death. Epinephrine is the primary medical therapy, and it must be administered promptly. This clinical report focuses on practical issues concerning the administration of self-injectable epinephrine for first-aid treatment of anaphylaxis in the community. The recommended epinephrine dose for anaphylaxis in children, based primarily on anecdotal evidence, is 0.01 mg/kg, up to 0.30 mg. Intramuscular injection of epinephrine into the lateral thigh (vastus lateralis) is the preferred route for therapy in first-aid treatment. Epinephrine autoinjectors are currently available in only 2 fixed doses: 0.15 and 0.30 mg. On the basis of current, albeit limited, data, it seems reasonable to recommend autoinjectors with 0.15 mg of epinephrine for otherwise healthy young children who weigh 10 to 25 kg (22-55 lb) and autoinjectors with 0.30 mg of epinephrine for those who weigh approximately 25 kg (55 lb) or more; however, specific clinical circumstances must be considered in these decisions. This report also describes several quandaries in regard to management, including the selection of dose, indications for prescribing an autoinjector, and decisions regarding when to inject epinephrine. Effective care for individuals at risk of anaphylaxis requires a comprehensive management approach involving families, allergic children, schools, camps, and other youth organizations. Risk reduction entails confirmation of the trigger, discussion of avoidance of the relevant allergen, a written individualized emergency anaphylaxis action plan, and education of supervising adults with regard to recognition and treatment of anaphylaxis.

Original languageEnglish (US)
Pages (from-to)638-646
Number of pages9
JournalPediatrics
Volume119
Issue number3
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

First Aid
Anaphylaxis
Epinephrine
Injections
Therapeutics
Intramuscular Injections
Quadriceps Muscle
Risk Reduction Behavior
Thigh
Allergens
Cause of Death
Hypersensitivity
Emergencies
Organizations
Education

Keywords

  • Anaphylaxis
  • Epinephrine
  • Food allergy
  • Insect-sting allergy
  • Self-injectable epinephrine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Sicherer, S. H., Simons, F. E. R., Williams, P. V., Bahna, S. L., Chipps, B. E., Fasano, M. B., ... Burrowes, D. (2007). Self-injectable epinephrine for first-aid management of anaphylaxis. Pediatrics, 119(3), 638-646. https://doi.org/10.1542/peds.2006-3689

Self-injectable epinephrine for first-aid management of anaphylaxis. / Sicherer, Scott H.; Simons, F. Estelle R.; Williams, Paul V.; Bahna, Sami L.; Chipps, Bradley E.; Fasano, Mary Beth; Lester, Mitchell R.; Virant, Frank S.; Welch, Michael J.; Kelso, John M.; Mahr, Todd A.; Ownby, Dennis Randall; Rachelefsky, Gary S.; Burrowes, Debra.

In: Pediatrics, Vol. 119, No. 3, 01.01.2007, p. 638-646.

Research output: Contribution to journalArticle

Sicherer, SH, Simons, FER, Williams, PV, Bahna, SL, Chipps, BE, Fasano, MB, Lester, MR, Virant, FS, Welch, MJ, Kelso, JM, Mahr, TA, Ownby, DR, Rachelefsky, GS & Burrowes, D 2007, 'Self-injectable epinephrine for first-aid management of anaphylaxis', Pediatrics, vol. 119, no. 3, pp. 638-646. https://doi.org/10.1542/peds.2006-3689
Sicherer SH, Simons FER, Williams PV, Bahna SL, Chipps BE, Fasano MB et al. Self-injectable epinephrine for first-aid management of anaphylaxis. Pediatrics. 2007 Jan 1;119(3):638-646. https://doi.org/10.1542/peds.2006-3689
Sicherer, Scott H. ; Simons, F. Estelle R. ; Williams, Paul V. ; Bahna, Sami L. ; Chipps, Bradley E. ; Fasano, Mary Beth ; Lester, Mitchell R. ; Virant, Frank S. ; Welch, Michael J. ; Kelso, John M. ; Mahr, Todd A. ; Ownby, Dennis Randall ; Rachelefsky, Gary S. ; Burrowes, Debra. / Self-injectable epinephrine for first-aid management of anaphylaxis. In: Pediatrics. 2007 ; Vol. 119, No. 3. pp. 638-646.
@article{18b88a5dad0a4e3885204dd302380b2e,
title = "Self-injectable epinephrine for first-aid management of anaphylaxis",
abstract = "Anaphylaxis is a severe, potentially fatal systemic allergic reaction that is rapid in onset and may cause death. Epinephrine is the primary medical therapy, and it must be administered promptly. This clinical report focuses on practical issues concerning the administration of self-injectable epinephrine for first-aid treatment of anaphylaxis in the community. The recommended epinephrine dose for anaphylaxis in children, based primarily on anecdotal evidence, is 0.01 mg/kg, up to 0.30 mg. Intramuscular injection of epinephrine into the lateral thigh (vastus lateralis) is the preferred route for therapy in first-aid treatment. Epinephrine autoinjectors are currently available in only 2 fixed doses: 0.15 and 0.30 mg. On the basis of current, albeit limited, data, it seems reasonable to recommend autoinjectors with 0.15 mg of epinephrine for otherwise healthy young children who weigh 10 to 25 kg (22-55 lb) and autoinjectors with 0.30 mg of epinephrine for those who weigh approximately 25 kg (55 lb) or more; however, specific clinical circumstances must be considered in these decisions. This report also describes several quandaries in regard to management, including the selection of dose, indications for prescribing an autoinjector, and decisions regarding when to inject epinephrine. Effective care for individuals at risk of anaphylaxis requires a comprehensive management approach involving families, allergic children, schools, camps, and other youth organizations. Risk reduction entails confirmation of the trigger, discussion of avoidance of the relevant allergen, a written individualized emergency anaphylaxis action plan, and education of supervising adults with regard to recognition and treatment of anaphylaxis.",
keywords = "Anaphylaxis, Epinephrine, Food allergy, Insect-sting allergy, Self-injectable epinephrine",
author = "Sicherer, {Scott H.} and Simons, {F. Estelle R.} and Williams, {Paul V.} and Bahna, {Sami L.} and Chipps, {Bradley E.} and Fasano, {Mary Beth} and Lester, {Mitchell R.} and Virant, {Frank S.} and Welch, {Michael J.} and Kelso, {John M.} and Mahr, {Todd A.} and Ownby, {Dennis Randall} and Rachelefsky, {Gary S.} and Debra Burrowes",
year = "2007",
month = "1",
day = "1",
doi = "10.1542/peds.2006-3689",
language = "English (US)",
volume = "119",
pages = "638--646",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "3",

}

TY - JOUR

T1 - Self-injectable epinephrine for first-aid management of anaphylaxis

AU - Sicherer, Scott H.

AU - Simons, F. Estelle R.

AU - Williams, Paul V.

AU - Bahna, Sami L.

AU - Chipps, Bradley E.

AU - Fasano, Mary Beth

AU - Lester, Mitchell R.

AU - Virant, Frank S.

AU - Welch, Michael J.

AU - Kelso, John M.

AU - Mahr, Todd A.

AU - Ownby, Dennis Randall

AU - Rachelefsky, Gary S.

AU - Burrowes, Debra

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Anaphylaxis is a severe, potentially fatal systemic allergic reaction that is rapid in onset and may cause death. Epinephrine is the primary medical therapy, and it must be administered promptly. This clinical report focuses on practical issues concerning the administration of self-injectable epinephrine for first-aid treatment of anaphylaxis in the community. The recommended epinephrine dose for anaphylaxis in children, based primarily on anecdotal evidence, is 0.01 mg/kg, up to 0.30 mg. Intramuscular injection of epinephrine into the lateral thigh (vastus lateralis) is the preferred route for therapy in first-aid treatment. Epinephrine autoinjectors are currently available in only 2 fixed doses: 0.15 and 0.30 mg. On the basis of current, albeit limited, data, it seems reasonable to recommend autoinjectors with 0.15 mg of epinephrine for otherwise healthy young children who weigh 10 to 25 kg (22-55 lb) and autoinjectors with 0.30 mg of epinephrine for those who weigh approximately 25 kg (55 lb) or more; however, specific clinical circumstances must be considered in these decisions. This report also describes several quandaries in regard to management, including the selection of dose, indications for prescribing an autoinjector, and decisions regarding when to inject epinephrine. Effective care for individuals at risk of anaphylaxis requires a comprehensive management approach involving families, allergic children, schools, camps, and other youth organizations. Risk reduction entails confirmation of the trigger, discussion of avoidance of the relevant allergen, a written individualized emergency anaphylaxis action plan, and education of supervising adults with regard to recognition and treatment of anaphylaxis.

AB - Anaphylaxis is a severe, potentially fatal systemic allergic reaction that is rapid in onset and may cause death. Epinephrine is the primary medical therapy, and it must be administered promptly. This clinical report focuses on practical issues concerning the administration of self-injectable epinephrine for first-aid treatment of anaphylaxis in the community. The recommended epinephrine dose for anaphylaxis in children, based primarily on anecdotal evidence, is 0.01 mg/kg, up to 0.30 mg. Intramuscular injection of epinephrine into the lateral thigh (vastus lateralis) is the preferred route for therapy in first-aid treatment. Epinephrine autoinjectors are currently available in only 2 fixed doses: 0.15 and 0.30 mg. On the basis of current, albeit limited, data, it seems reasonable to recommend autoinjectors with 0.15 mg of epinephrine for otherwise healthy young children who weigh 10 to 25 kg (22-55 lb) and autoinjectors with 0.30 mg of epinephrine for those who weigh approximately 25 kg (55 lb) or more; however, specific clinical circumstances must be considered in these decisions. This report also describes several quandaries in regard to management, including the selection of dose, indications for prescribing an autoinjector, and decisions regarding when to inject epinephrine. Effective care for individuals at risk of anaphylaxis requires a comprehensive management approach involving families, allergic children, schools, camps, and other youth organizations. Risk reduction entails confirmation of the trigger, discussion of avoidance of the relevant allergen, a written individualized emergency anaphylaxis action plan, and education of supervising adults with regard to recognition and treatment of anaphylaxis.

KW - Anaphylaxis

KW - Epinephrine

KW - Food allergy

KW - Insect-sting allergy

KW - Self-injectable epinephrine

UR - http://www.scopus.com/inward/record.url?scp=33947118581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947118581&partnerID=8YFLogxK

U2 - 10.1542/peds.2006-3689

DO - 10.1542/peds.2006-3689

M3 - Article

VL - 119

SP - 638

EP - 646

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 3

ER -